Reimagine Cancer Detection, Diagnosis & Patient Management through Harnessing the Potential of Liquid Biopsies
In the past year, the detection and characterization of fluid-based biomarkers in oncology witnessed an unprecedented level of progress, investment and industry partnership announcements. However, as the liquid assay landscape matures and the level of sensitivity and selectivity achieved by assays creates excitement for precision drug development, there remains a number of unique hurdles to translate rapid technical advancements towards the development of more effective and accessible precision oncology treatments.
That’s why the 6th Liquid Biopsy for Precision Oncology Summit took place digitally in February, providing you with a valuable industry touchpoint to network, collaborate and learn directly from your peers at an exciting time for precision medicine.
As industry’s most comprehensive liquid biopsy meeting, uniting 600 key decision makers including Pfizer, AstraZeneca, Mirati Therapeutics, Kura Oncology, GSK, BloodPAC, International Society of Liquid Biopsy, Guardant Health, Natera and many more to address the key scientific, technical, regulatory, commercial and testing access challenges associated with progressing precision oncology pipelines harnessing liquid biopsy technology.
Exploring how a breadth of methods including ddPCR, single-cell genotypic & phenotypic analysis, in addition to pan-cancer, comprehensive NGS & tumor-informed assays are enabling detection screening, earlier diagnosis, resistance and recurrence monitoring – in turn facilitating quicker and more informed treatment decision-making in precision drug development.
Attendees joined to witness first-hand the clinical utility of ctDNA, cfDNA, miRNA & CTC analysis in the precision oncology pipelines of 30+ scientific & commercial biopharma & academic experts successfully advancing immunotherapy and targeted candidates toward patients.
A prime opportunity to meet diverse stakeholders and discover the most cutting-edge scientific data to strengthen your pipeline and capitalize on the vast amount of progress the field is witnessing.
A crucial annual date on the precision oncology’s industry calendar – It’s not to be missed!
President, Chief Executive Officer & Co-Founder
Executive Director, Head of Biomarkers & Companion Diagnostics
Scientific Program Manager, Cancer Research Partnerships
Foundation for the National Institutes of Health
Professor, Director, Thoracic Oncology Program; Chief Medical Officer
UC Davis Comprehensive Cancer Center; International Society for Liquid Biopsy
Scientific Director, Oncology Diagnostics
Executive Director, Clinical Biomarkers & Companion Diagnostics
Senior Director, Translational Oncology Lead, Global Product Development
Global Precision Medicine Strategic Intelligence Lead
Director of Precision Medicine Quality Initiatives & Partnerhips
Living with Metastatic Breast Cancer
Vice President Translational Medicine & Companion Diagnostics
Chairman, Institute Director
University Medical Center Hamburg-Eppendorf
Head of Translational Medicine
Senior Director, Operations & Medical Development
Research Chair, Department of Oncology; Consultant, Department of Laboratory Medicine and Pathology
Medical Director, CDx & Biomarker Strategy
Director Colon Cancer Research; Precision Medicine Director for Liquid Biopsy Research
Weill Cornell Medicine; Englander Institute of Precision Medicine
Director, Clinical Biomarkers, ImmunoOncology
Head of Clinical Biomarkers
Don’t take our word for it! Here’s what past attendees had to say at last year’s digital meeting!
“I learned the latest progress in use of liquid biopsy in both the research and clinical setting. Wouldn't miss this meeting” – Genentech
““Extremely informative sessions which provide insight into both the clinical and commercial potential of liquid biopsy” – Myriad Genetics
“Liquid Biopsy has finally come of age as evident by the speakers and presentations given at the Liquid Biopsy Summit” – Regeneron